Thesis
We hold a rare position within the healthtech industry, which represents our commitment to a new paradigm shift. We invest in scientific proof across disciplines. Our goal is to maximize impact and improve health at scale.
We believe the science to address root causes of chronic illness and disease already exists but lacks accessibility, affordability and adoption.
We built a one-of-a-kind platform in a category that almost no institutional investor covers properly or in totality.
Most chronic disease is rooted in metabolic disruption. We seek resolution over lifelong symptom management, underwriting the biology and cellular foundations beneath the diagnosis — a fortified terrain, the human body.
Brain health cannot be separated from metabolic health. We back protocols, biomarkers and platforms that protect cognition, reduce brain fog and extend brain longevity for individuals and the broader public.
From elite athletes to family offices to everyday people, we invest in the science of performing at the highest level — sustained, repeatable and grounded in measurable science.
What is not measured cannot be improved. We require independent verification, repeatability, transparency and complete disclosure, with multimodal data — genomics, epigenomics, blood biomarkers and brain activity — captured and turned into actionable intervention.
As digital transformation reshaped the last era, AI transformation is reshaping this one. AI runs as a cross-functional layer across the portfolio — modernizing systems, personalizing recommendations and scaling with discipline.